Kronox Lab Sciences Limited has informed the Exchange regarding 'Submission of Financial Results in Machine Readable Format for the BM held on 22nd May, 2025'.
KRONOX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.9 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kronox Lab Sciences reported FY25 revenue from operations of Rs. 10,019.39 lakhs, up 11.5% from Rs. 8,986.24 lakhs in FY24. Profit after tax grew to Rs. 2,546.71 lakhs vs Rs. 2,135.13 lakhs, a 19.3% rise, with EPS improving to Rs. 6.91 from Rs. 5.81. Q4 FY25 revenue rose to Rs. 2,613.11 lakhs (vs Rs. 2,217.64 lakhs in Q4 FY24) and Q4 PAT came in at Rs. 6,31.52 lakhs. Operating cash flow remained healthy at Rs. 3,069.66 lakhs (vs Rs. 1,741.51 lakhs). The statutory auditor (Mahesh Udhwani & Associates) issued an unmodified opinion, and the company operates in a single segment — high-purity specialty fine chemicals.
Solid double-digit revenue growth, ~20% PAT growth, and expanding margins signal improving business momentum for shareholders. A clean audit report with unmodified opinion removes any near-term concerns about earnings quality.